A new study has shown that anti-rejection drugs used for people who have had a transplant could protect against Alzheimer's disease.
Researchers at the University of Texas Medical Branch at Galveston has revealed that calcineurin inhibitor-based medications could help to prevent the neurodegenerative disease.
Published in the Journal of Alzheimer's Disease, the study looked at calcineurin, an enzyme that has been shown to regulate communication between brain cells and memory formation.
Previous research has shown that it plays a key role in Alzheimer's as high levels of calcineurin are found in the nervous system of people with the disease.
The team looked at the medical records of 2,644 patients who received organ transplants and take calcineurin inhibitor-based medications. They looked for any evidence of memory impairment or dementia, which is constantly monitored as it can affect treatment compliance.
These findings were then compared with national data obtained from the 2014 Alzheimer's Association Facts and Figures dataset on age-matched patients to compare the prevalence of Alzheimer's.
They found that the prevalence of dementia and Alzheimer's in the transplant group was much lower than the general population, finding just 1.02 per cent of the study subjects with the condition compared to 11 per cent of the general population.
Posted by Edward Bartel
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.